Status: Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
Participants needed: 435
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Jul 2, 2026Locations: 185
Eligibility criteria
Participant must be ≥ 12 years of age at the time of signing the informed consen... [+8]
Primary lung diagnosis other than bronchiectasis [+11]